RxDoctor Payments Data

Jordan Dutter, MD

Family Medicine · Flora, INNPI 1730157835

Payments from drug & device makers

$9,659in general payments, 2019–2025

Across 652 payments — averaging $14.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$926
  • Amgen$557
  • Astellas Pharma US Inc$344
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$9,647100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,659 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$189,743
Medicare patients
513
Services billed
3,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin166$207,105
MounjaroTirzepatide144$179,079
OzempicSemaglutide85$152,573
EliquisApixaban140$150,110
Enbrel SureclickEtanercept12$84,080
FarxigaDapagliflozin Propanediol60$68,653
TrulicityDulaglutide31$48,534
Tresiba Flextouch U-200Insulin Degludec20$31,839
FanaptIloperidone11$27,363
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$27,353
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$22,017
CaplytaLumateperone Tosylate13$20,310
XareltoRivaroxaban13$18,721
Nurtec OdtRimegepant Sulfate11$18,051
EntrestoSacubitril/Valsartan14$16,779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$926$227,613175 claims
Boehringer IngelheimJardiance, Tradjenta$242$218,516177 claims
Novo NordiskOzempic, Fiasp$1,329$169,330109 claims
PfizerEliquis, Nurtec Odt$221$168,162151 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,044$96,00592 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$93$20,31013 claims
NovartisEntresto$111$16,77914 claims
GSKBreo Ellipta$302$8,69916 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$55$4,16512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Flora

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →